Regencell Bioscience/$RGC
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Regencell Bioscience
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
Ticker
$RGC
Sector
Primary listing
Employees
-
Headquarters
Causeway Bay, Hong Kong
Website
RGC Metrics
BasicAdvanced
$9.1B
-
-$0.01
2.28
-
Price and volume
Market cap
$9.1B
Beta
2.28
52-week high
$83.60
52-week low
$0.09
Average daily volume
260K
Financial strength
Profitability
EBITDA (TTM)
-4.091
Management effectiveness
Return on assets (TTM)
-30.65%
Return on equity (TTM)
-47.77%
Valuation
Price to book
1,357.88
Price to tangible book (TTM)
1,357.88
Growth
Earnings per share change (TTM)
-13.20%
3-year earnings per share growth (CAGR)
-8.31%
RGC Financial Performance
Revenues and expenses
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Regencell Bioscience stock?
Regencell Bioscience (RGC) has a market cap of $9.1B as of October 10, 2025.
What is the P/E ratio for Regencell Bioscience stock?
The price to earnings (P/E) ratio for Regencell Bioscience (RGC) stock is 0 as of October 10, 2025.
Does Regencell Bioscience stock pay dividends?
No, Regencell Bioscience (RGC) stock does not pay dividends to its shareholders as of October 10, 2025.
When is the next Regencell Bioscience dividend payment date?
Regencell Bioscience (RGC) stock does not pay dividends to its shareholders.
What is the beta indicator for Regencell Bioscience?
Regencell Bioscience (RGC) has a beta rating of 2.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.